ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2017; 7(11): 172-176


Determinants of Gastroesophageal Reflux Disease (GERD) severity and Utilization of Proton Pump Inhibitors Among GERD Patients: A Cross-Sectional Study

Jinin S. Mathew, M. R. V. Nandini, G. R. Saraswathy, Viswam Subeesh, Eswaran Maheswari.




Abstract

Background: Proton Pump Inhibitors (PPIs) are the first line agents in the treatment of gastro-esophageal reflux disease (GERD). The efficiency and safety profile of PPIs have driven to its over-utilization and the protracted recipients are targets to its long-term adverse such as chronic kidney disease (CKD), Clostridium difficile infection and community-acquired pneumonia etc. Therefore, the study was intended to explore the PPI utilization patterns in GERD patients in an Indian tertiary-care hospital.
Materials and Methods: A cross-sectional study was carried out at the Department of Gastroenterology, in a private tertiary care hospital, Bangalore, for a period of six months. The objective of the study was to identify the risk factors of GERD and prescribing trends of proton pump inhibitors in GERD patients.
Results: Among the 139 patients diagnosed with GERD, 66% were males. GERD was found to be more prevalent in the age group of 25-44 years. The GERD patients reported a relationship between the severity of disease and the following risk factors, namely, Smoking, OR: 0.446, alcoholism, OR: 1.26, BMI>24.9, OR:1.13 and mixed diet, OR:0.486). Rabeprazole (36.4%) was the commonly prescribed PPI. PPI combination therapy was prescribed in 56.11% of patients, followed by single therapy in 39.5% patients.
Conclusion: Creating awareness among the clinicians and patients on appropriate use of PPIs can reduce the additional economic burden and improve the health-related quality of life. Focusing on risk factors to identify preventive measures will help in decreasing the incident rate of GERD.

Key words: Proton pump inhibitors (PPIs); Gastro-esophageal reflux disease (GERD); prescription pattern; non-erosive reflux disease (NERD); erosive esophagitis (EE).






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.